Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Innospec Inc is a specialty chemicals business based in the US. Innospec shares (IOSP) are listed on the NASDAQ and all prices are listed in US Dollars. Innospec employs 1,900 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $95.79 |
|---|---|
| 52-week range | $80.03 - $106.87 |
| 50-day moving average | $98.09 |
| 200-day moving average | $92.72 |
| Wall St. target price | $117.50 |
| PE ratio | 21.9171 |
| Dividend yield | $1.16 (1.42%) |
| Earnings per share (TTM) | $4.27 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $95.79 from 2022-06-30
| 1 week (2022-06-24) | 2.31% |
|---|---|
| 1 month (2022-05-29) | N/A |
| 3 months (2022-03-30) | 3.01% |
| 6 months (2021-12-31) | 6.03% |
| 1 year (2021-07-02) | 5.86% |
|---|---|
| 2 years (2020-07-02) | 22.24% |
| 3 years (2019-07-02) | 3.62% |
| 5 years (2017-06-30) | 46.13% |
Valuing Innospec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innospec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innospec's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Innospec shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Innospec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $194.5 million.
The EBITDA is a measure of a Innospec's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.6 billion |
|---|---|
| Operating margin TTM | 9.4% |
| Gross profit TTM | $434.9 million |
| Return on assets TTM | 6.23% |
| Return on equity TTM | 10.47% |
| Profit margin | 6.57% |
| Book value | $43.05 |
| Market capitalisation | $2.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 23.11% of net profits
Recently Innospec has paid out, on average, around 23.11% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.42% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Innospec shareholders could enjoy a 1.42% return on their shares, in the form of dividend payments. In Innospec's case, that would currently equate to about $1.16 per share.
While Innospec's payout ratio might seem low, this can signify that Innospec is investing more in its future growth.
Innospec's most recent dividend payout was on 25 May 2022. The latest dividend was paid out to all shareholders who bought their shares by 15 May 2022 (the "ex-dividend date").
Innospec's shares were split on a 2:1 basis on 22 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Innospec shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Innospec shares which in turn could have impacted Innospec's share price.
Over the last 12 months, Innospec's shares have ranged in value from as little as $80.0302 up to $106.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innospec's is 1.1747. This would suggest that Innospec's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in various fuels. This segment's products are used in the operation of automotive, marine, and aviation engines; power station generators; and heating oil. Its Performance Chemicals segment provides technology-based solutions for its customers' processes or products that focuses on the personal care, home care, agrochemical, and metal extraction markets. The company's Oilfield Services segment develops and markets chemical solutions for fracturing, stimulation, and completion operations; and products for oil and gas production, as well as products to prevent loss of mud in drilling operations. It sells its products primarily to oil and gas exploration and production companies, oil refineries, fuel manufacturers and users, personal care and home care companies, formulators of agrochemical and metal extraction formulations, and other chemical and industrial companies.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.